METHODS AND COMPOSITIONS FOR VASCULOGENIC POTENTIAL DETERMINATION

• US 20100035297A1
• Filed: 08/06/2009
• Published: 02/11/2010
• Est. Priority Date: 08/08/2008
• Status: Abandoned Application

• Current Assignee: Indiana University Research & Technology Corporation (Indiana University)
• Original Assignee: Indiana University Research & Technology Corporation (Indiana University)
• Inventors: Traktuev, Dmitry O.
• Application Number:
  US12/537,077
• Publication Number:
  US 20100035297A1
• Time in Patent Office: Days
• US Class Current: 435/29
• CPC Class Codes: G01N 2500/10 involving cells
• CPC Class Codes: G01N 33/5044 involving specific cell types
• CPC Class Codes: G01N 33/5064 Endothelial cells

Abstract

Methods and compositions to evaluate the therapeutic vasculogenic potential of a variety of cells including endothelial cells using a monolayer of pericytic cells are disclosed. Pericytic cells or mural cells including those isolated from adipose tissue, such as for example, adipose stromal cells (ASC) or adipose-derived stromal cells (ADSCs) provide suitable conditions that stimulate endothelial cells from different origins to modulate stable vascular network organization in an in vitro experimental setting. Compositions that contain premixed ASC and EC are suitable for testing a candidate agent'"'"'s angiogenic or antiangiogenic potential.

Claims

1. A method of evaluating vasculogenic potential of endothelial cells, the method comprising:

(a) culturing the endothelial cells (EC) and a plurality of adipose stromal cells (ASC); and

(b) evaluating the vasculogenic potential by the formation of a vascular network.

2. The method of claim 1, wherein the endothelial cells are cultured on a layer of adipose stromal cells.

3. The method of claim 1, wherein the endothelial cells and adipose stromal cells are pre-mixed prior to culturing.

4. The method of claim 1, wherein the endothelial cells are derived from a source selected from the group consisting of placenta, peripheral blood, vessel wall, cord blood, umbilical vein, cardiac microvascular cells, adipose tissue, saphenius vein, HUVEC, HmVEC, and ECFC.

5. The method of claim 1, wherein the adipose stromal cells are adherent.

6. The method of claim 1, wherein the adipose stromal cells are CD34⁺CD45−

CD31⁻

.

7. The method of claim 5, wherein the adherent cells express a marker selected from the group consisting of CD10, CD13, and CD90.

8. The method of claim 1, wherein the adipose stromal cells express a marker selected from the group consisting of chondroitin sulfate proteoglycan (NG2), CD140a, and CD140b (PDGF receptor- and -β

, respectively).

9. The method of claim 1, wherein the endothelial cells are selected from the group consisting of mature endothelial cells, endothelial progenitor cells (EPC) and endothelial colony forming cells (ECFC).

10. The method of claim 1, wherein the endothelial cells are CD31⁺CD144⁺.

11. The method of claim 2, wherein the wherein the adipose stromal cells are grown as a monolayer.

12. The method of claim 1, wherein the adipose stromal cells are seeded at an initial density of about 3,500-240,000 cells/cm² and the endothelial cells are seeded at an initial density of about 625-25,000 cells/cm².

13. The method of claim 1, wherein the adipose stromal cells and endothelial cells are mixed at a ratio of about 5:

1 to about 100;

1.

14. The method of claim 1, wherein the adipose stromal cells are cultured for about 3 hours prior to adding the endothelial cells.

15. The method of claim 1, wherein the adipose stromal cells and the endothelial cells are generally homogenous and substantially pure.

16. The method of claim 1, wherein the adipose stromal cells and the endothelial cells are cultured substantially free of one or more exogenously introduced components of the extracellular matrix (ECM).

17. A method of screening a candidate angiogenic or anti-angiogenic agent, the method comprising:

(a) culturing adipose stromal cells and endothelial cells capable of forming a vascular network in vitro;

(b) contacting adipose stromal cells and endothelial cells with the candidate agent; and

(c) determining that the candidate agent is angiogenic or anti-angiogenic if the candidate compound augments angiogenesis or inhibits angiogenesis by the comparing the vascular network formation to a control sample without the candidate compound.

18. An assay kit comprising an effective amount of endothelial cells and adipose stromal cells (ASC), wherein the adipose stromal cells and endothelial cells (EC) are mixed at a ratio of about 5:

1 to about 100;

1.

19. The kit of claim 29, wherein the cells are frozen in a vial.

20. The kit of claim 29, wherein the ASC are about 200,000-5,000,000 cells and the endothelial cells are about 200,000-2,000,000 cells.